Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • pharma-news
    • Complaints against...

    Complaints against Anti TB Dept, RITES India, Central Medical Service Society dismissed by CCI

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 16 Feb 2020 5:00 AM  |  Updated On 16 Feb 2020 5:01 AM
    Complaints against Anti TB Dept, RITES India, Central Medical Service Society dismissed by CCI

    The order came after it was alleged that the Central Medical Service Society and RITES India had published tenders for procurement of anti-TB and anti-HIV drugs from suppliers having Geneva WHO-Prequalified certificate.

    New Delhi: The Competition Commission of India has disposed of complaints of unfair business practices against Central Medical Service Society, Anti TB Department and RITES India, noting that asking drug suppliers to have a WHO certification for supply of drugs treating critical diseases cannot be termed as arbitrary.

    The order came after it was alleged that the Central Medical Service Society and RITES India had published tenders for procurement of anti-TB and anti-HIV drugs from suppliers having Geneva WHO-Prequalified certificate.

    According to the complainant, the condition of certification was incorporated in order to create a monopoly of few companies and thus allegedly abused their dominant market position.

    CCI said, "Such certification is a globally accepted standard of quality, safety and efficacy and the same would have been incorporated in the tender to improve the quality standards of the drug and public safety."

    It also said, "such a condition for supplying drugs for treating the critical diseases, on the face of it, cannot be termed as arbitrary or favouring the particular companies unless the same is wholly irrelevant or illusory".

    On allegations of abuse of dominant position, CCI said there is no information to show that the entities are dominant procurers in the market for procurement of anti-TB/HIV drugs.

    "The dominance of an enterprise in the relevant market has to be prima facie established before pressing into service the provisions of the Act relating to abuse of dominant position," it added.

    The entities are also alleged to have violated provisions of the Drugs and Cosmetics Act, 1940. However, CCI said the remedy for such alleged violations does not lie under the Competition Act and the complainant may approach the relevant authorities for redressal of its grievances.

    Read also: Indian-origin pharmacy technician held guilty of illegally distributing oxycodone pills

    CCICentral Medical Service SocietyAnti TB DeptRITESHIV drugstb drugswhodrugs and cosmetics act
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok